nach oben

Erschienen in:

01.08.2012 | Maternal-Fetal Medicine

Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy

verfasst von: El-Said Abdel-Hady, Reda Abdel-Hady Hemida, Anas Gamal, Maha El-Zafarany, Eman Toson, Mohammed Attia El-Bayoumi

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To study the outcome of pregnancies complicated by malignant disease, in particular neonatal morbidity and mortality after in utero exposure to chemotherapy.

Methods

This prospective study included 118 patients diagnosed with malignant disease for the first time during pregnancy over an 8-year period (March 2003–March 2011). Outcome of neonates born to mothers who received chemotherapy during pregnancy was studied and compared with a control group.

Results

The commonest cancer type diagnosed during pregnancy (56/118 = 47.45 %) was breast carcinoma followed by lymphoma/leukemia (32 = 27.12 %). Gynecological tumors (all ovarian) represented 10.16 %, soft tissue tumors 5.08 %, colorectal 4.23 %, thyroid 2.54 % and others 3.38 %.

Sixty-one (51.64 %) women received chemotherapy (average 3 ± 2 cycles) during the second and third trimesters. The incidence of neonatal survival, preterm birth, small for gestational age and congenital malformations was not significantly different between women who received chemotherapy during pregnancy and the control group. Five (4.23 %) women with advanced disease died during or shortly after termination of pregnancy.

Conclusion

In utero exposure to chemotherapy during the second and third trimesters of pregnancy carries minimal morbidity to the unborn fetus.

De Carolis S, Grimolizzi F, Garofalo S, Fatigante G, Ferrazzani S, Carducci B, Caruso A (2006) Cancer in pregnancy: results of a series of 32 patients. Anticancer Res 26(3B):2413–2418PubMed

Zanetti-Dällenbach R, Wight E (2005) Chemotherapy for gynecological malignancies—a contraindication during pregnancy? Ther Umsch 62(1):53–60PubMedCrossRef

Ibrahim EM, Ezzat AA, Baloush A, Hussain ZH, Mohammed GH (2000) Pregnancy-associated breast cancer: a case–control study in a young population with a high-fertility rate. Med Oncol 17(4):293–300PubMedCrossRef

Woo JC, Yu T, Hurd TC (2003) Breast cancer in pregnancy: a literature review. Arch Surg 138(1):91–98PubMedCrossRef

Azim HA, Botteri E, Renne G, Dell’orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M, Sotiriou C, Piccart M, Goldhirsch A, Viale G, Peccatori FA (2011) The biological features and prognosis of breast cancer diagnosed during pregnancy: a case–control study. Acta Oncol [Epub ahead of print]

Brewer M, Kueck A, Runowicz CD (2011) Chemotherapy in pregnancy. Clin Obstet Gynecol 54(4):602–618PubMedCrossRef

Langagergaard V (2010) Birth outcome in women with breast cancer, cutaneous malignant melanoma, or Hodgkin’s disease: a review. Clin Epidemiol 3:7–19PubMed

Keleher AJ, Theriault RL, Gwyn KM, Hunt KK, Stelling CB, Singletary SE, Ames FC, Buchholz TA, Sahin AA, Kuerer HM (2002) Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg 194(1):54–64PubMedCrossRef

Valachis A, Tsali L, Pesce LL, Polyzos NP, Dimitriadis C, Tsalis K, Mauri D (2010) Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv 65(12):786–793PubMedCrossRef

10.

Cardonick E, Iacobucci A (2004) Use of chemotherapy during human pregnancy. Lancet Oncol 5:283–291PubMedCrossRef

11.

Potluri V, Lewis D, Burton GV (2006) Chemotherapy with taxanes in breast cancer during pregnancy: case report and review of the literature. Clin Breast Cancer 7:167–170PubMedCrossRef

12.

Gainford MC, Clemons M (2006) Breast cancer in pregnancy: are taxanes safe? Clin Oncol 18:159CrossRef

13.

Fenig E, Mishaeli M, Kalish Y, Lishner M (2001) Pregnancy and radiation. Cancer Treat Rev 27:1–7PubMedCrossRef

14.

Sagan D, Semczuk A, Lampka E (2010) Combination chemotherapy for Hodgkin’s lymphoma during pregnancy: favorable outcome for mother and child. J Obstet Gynaecol Res 36(4):882–886PubMedCrossRef

15.

Gadducci A, Cosio S, Fanucchi A, Nardini V, Roncella M, Conte PF, Genazzani AR (2003) Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. Anticancer Res 23(6D):5225–5229PubMed

16.

Abdel-Hady ES, Emam M, Al-Gohary A, Hassan M, Farag MK, Abo-Elkheir M (2006) Screening for cervical carcinoma using visual inspection with acetic acid. Int J Gynaecol Obstet 93(2):118–122PubMedCrossRef

17.

Gambino A, Gorio A, Carrara L, Agoni L, Franzini R, Lupi GP, Maggino T, Romagnolo C, Sartori E, Pecorelli S (2011) Cancer in pregnancy: maternal and fetal implications on decision-making. Eur J Gynaecol Oncol 32(1):40–45PubMed

18.

Aviles A, Neri N (2001) Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2:173–177PubMedCrossRef

19.

Abadi U, Koren G, Lishner M (2011) Leukemia and lymphoma in pregnancy. Hematol Oncol Clin North Am 25(2):277–291PubMedCrossRef

20.

Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA (2005) Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 23(18):4192–4197PubMedCrossRef

21.

Hoellen F, Reibke R, Hornemann K, Thill M, Luedders DW, Kelling K, Hornemann A, Bohlmann MK (2012) Cancer in pregnancy. Part I: basic diagnostic and therapeutic principles and treatment of gynecological malignancies. Arch Gynecol Obstet 285(1):195–205PubMedCrossRef

22.

Hoellen F, Reibke R, Hornemann K, Thill M, Luedders DW, Kelling K, Hornemann A, Bohlmann MK (2011) Cancer in pregnancy. Part II: treatment options of breast and other non-gynecological malignancies. Arch Gynecol Obstet 284(6):1481–1494PubMedCrossRef

Titel: Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy
verfasst von: El-Said Abdel-Hady
Reda Abdel-Hady Hemida
Anas Gamal
Maha El-Zafarany
Eman Toson
Mohammed Attia El-Bayoumi
Publikationsdatum: 01.08.2012
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2287-5

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Internistische Arzneimitteltherapie Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy